ZHONG JI LS affiliated Zhongli Hainan plans to jointly establish an "International Precision Medicine Center for Oncology" with Hainan Boao
ZHONG JI LS announced that its indirect non-wholly-owned subsidiary Zhongli (Hainan) has signed a cooperation agreement with Hainan Boao to jointly establish the "International Precision Medicine Center for Oncology." Hainan Boao is responsible for providing the venue and service functions, while Zhongli Hainan is responsible for the operation and technical support of the center. The board believes that this cooperation will promote the development of longevity science business, expand the domestic market, and bring stable revenue growth to the group
According to the Zhitong Finance APP, ZHONG JI LS (00767) announced that on September 13, 2025, its indirect non-wholly-owned subsidiary Zhongli (Hainan) Life Science Technology Co., Ltd. (Zhongli Hainan) signed a cooperation agreement (the Cooperation Agreement) with Hainan Boao Super Hospital Co., Ltd. (Hainan Boao). Zhongli Hainan and Hainan Boao will jointly establish the "International Oncology Precision Medicine Center" (the Medical Center), with Hainan Boao responsible for providing the venue and the service functions of the "1+X" platform, including but not limited to: outpatient services, hospitalization, examinations, treatments, surgeries, etc. Zhongli Hainan will be responsible for the operation of the center and provide expert and specialized technical and equipment support. Both parties will jointly carry out diagnosis and treatment activities and various research projects for patients.
The Board of Directors believes that the market prospects for longevity science are broad, as it has been observed that wealthy clients globally are more willing to accept and spend on longevity science applications to enhance their overall health and immune status, and promote their physical rejuvenation.
The signing of the Cooperation Agreement aligns with the Group's development strategy and plan for longevity science business, which will benefit the Group's future business development and lay a solid foundation for further expanding the domestic market. The Board believes that the signing of the Cooperation Agreement will further improve the Group's layout in the field of longevity science diagnosis and medical services, opening up new sources of income in longevity science, with the aim of bringing more stable and sustainable growth in revenue for the Group in the long term
